Product

Ranbaxy announces launch of Atorvastatin, generic Lipitor®, in the U.S.

Ranbaxy Pharmaceuticals Inc., a wholly owned subsidiary of Ranbaxy Laboratories Ltd. (RLL, NSE: RANBAXY, BSE: 500359) ("Ranbaxy"), today announced that it has received final approval from the U.S. Food and Drug Administration to manufacture and market Atorvastatin and has launched the product in the U.S. market.

Hits: 7160

Read more ...

Forest Laboratories and Nycomed Receive Complete Response Letter for Roflumilast

Forest Laboratories, Inc.Forest Laboratories, Inc. (NYSE: FRX) and Nycomed announced that the U.S. Food and Drug Administration (FDA) issued a complete response letter regarding the New Drug Application (NDA) for roflumilast.

Hits: 4225

Read more ...

Saudi Food and Drug Authority Suspends The Authorisation of Rosiglitazone (Avandia®)

The Saudi food and Drug Authority has reviewed the safety of Rosiglitazone (Avandia®) which used in treatment of type 2 diabetes mellitus and marketed in Saudi Arabia as Avandia®.

Hits: 4851

Read more ...

Novel Drug for Chronic Management of Hyperuricemia in Gout Patients

Teijin Pharma Limited announced the European launch of TMX-67 (febuxostat), a novel drug discovered by Teijin Pharma for the treatment of hyperuricemia in patients with gout. Ipsen, a global biotechnology specialty care group and the TMX-67 licensee in Europe, and its sublicensee the Menarini Group, the first Italian pharmaceutical group in the world, have began marketing the product in Europe under the brand name ADENURIC(r).

Hits: 4395

Read more ...

FDA Grants IBsolvMIR Orphan Drug designation in the treatment of diabetes patients in the U.S.

TikoMed AB, a biotechnology company focused on development and commercialization of innovative treatments for immune diseases and cell therapies, today announced that IBsolvMIR® has been granted orphan drug designation for the prevention of graft rejection of pancreatic islet transplantation by the U.S. Food and Drug Administration (FDA).

Hits: 4858

Read more ...

Orphan Drug Designation for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS)

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) announced today that Soliris(R) (eculizumab), its first-in-class complement inhibitor, has been granted Orphan Medicinal Product Designation by the European Commission for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS).

Hits: 4146

Read more ...

Schering-Plough Announces European Filing of SYCREST(R) (asenapine)

Schering-Plough CorporationSchering-Plough Corporation (NYSE: SGP) announced that the European Medicines Agency (EMEA) has validated (accepted for review) the company's Marketing Authorization Application (MAA) for SYCREST(R) (asenapine) sublingual tablets for the treatment of schizophrenia and manic episodes associated with bipolar I disorder.

Hits: 4301

Read more ...

Most Popular Now

One family's history of the rare co…

In recognition of International Fabry Awareness month, Shire has released the trailer for Our Fabry Family Tree, a short film series featuring a family who were unknowing...

Read more

What's the secret to living a full …

If you have ever asked yourself, "What makes me feel most fulfilled?" you are not alone. Nearly 2 million people recently answered that question in a new survey by Abbott...

Read more

Bristol-Myers Squibb reports first …

Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the first quarter of 2016, which were highlighted by strong sales for Opdivo, Eliquis and our hepatitis...

Read more

Researchers discover potential trea…

Researchers at the Icahn School of Medicine at Mount Sinai say that tiny doses of a cancer drug may stop the raging, uncontrollable immune response to infection that lead...

Read more

Bayer off to a successful start in …

The Bayer Group got off to a successful start in the new fiscal year. "All segments posted gains in their operating performance," said CEO Dr. Marijn Dekkers when he pres...

Read more

Ready. Raise. Rise. Campaign

The Ready. Raise. Rise. campaign encourages everyone to raise and share a flag to salute those who have been touched by cancer, especially patients and caregivers, and le...

Read more

Pfizer reports first-quarter 2016 r…

Pfizer Inc. (NYSE: PFE) reported financial results for first-quarter 2016 and updated certain components of its 2016 financial guidance. Reported revenues totaled $13.0 b...

Read more

Research points to a new treatment …

Researchers have shown how controlling cholesterol metabolism in pancreatic cancer cells reduces metastasis, pointing to a potential new treatment using drugs previously ...

Read more

'Mediterranean' diet linked to lowe…

A "Mediterranean" diet, high in fruit, vegetables, fish and unrefined foods, is linked to a lower risk of heart attack and stroke in people who already have heart disease...

Read more

Merck brings international start-up…

Merck, a leading science and technology company, has announced the participants for its Accelerator Programs in Darmstadt and Nairobi. Almost 200 highly competitive appli...

Read more

AstraZeneca completes acquisition o…

AstraZeneca has completed the acquisition of the core respiratory business of Takeda Pharmaceutical Company Limited ("Takeda"). The agreement, announced in December 2015...

Read more

Why are women less likely to be pre…

Statins are equally effective at decreasing risk of coronary events in men and women, and yet women are less likely to be prescribed these cholesterol-lowering drugs than...

Read more

Digest World Pharma Newsletter

Subscribe to our weekly Digest World Pharma Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]